Zurich Cantonal Bank’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Zurich Cantonal Bank’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,792	Closed	-$407K	–	2882
2023 Q1	$407K	Buy	3,792 +1,139	+43%	+$131K	﹤0.01%	1415
2022 Q4	$292K	Sell	2,653 -244	-8%	-$15.8K	﹤0.01%	1585
2022 Q3	$171K	Buy	2,897 +662	+30%	+$30.3K	﹤0.01%	1843
2022 Q2	$63K	Sell	2,235 -54	-2%	-$1.56K	﹤0.01%	2490
2022 Q1	$86K	Buy	+2,289	New	+$90.5K	﹤0.01%	2346

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Zurich Cantonal Bank's RXDX Position: Q2 2023 in Review

Zurich Cantonal Bank sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,792 shares — an estimated $407K sold.

Zurich Cantonal Bank first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $407K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Zurich Cantonal Bank reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Zurich Cantonal Bank sold 3,792 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $407K.
Zurich Cantonal Bank first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Zurich Cantonal Bank's Prometheus Biosciences, Inc. Common Stock position peaked at $407K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Zurich Cantonal Bank's 13F filing for Q2 2023, filed 7 Aug 2023.